Rimegepant
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Using the evidence pack as provided — no additional skill applies here since this is a direct content-generation task following an explicit template, not a coding/debugging task.
Rimegepant: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist (“gepant”) already used internationally for the acute and preventive treatment of migraine, though it is not yet marketed in this jurisdiction. The TxGNN model predicts it may also be effective for Migraine with Brainstem Aura, a specific migraine subtype, with 0 dedicated clinical trials for this subtype but 13 supporting publications on rimegepant’s broader migraine efficacy and safety profile.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in structured regulatory data (drug not yet marketed here); per literature, rimegepant is approved elsewhere for acute treatment of migraine with/without aura and preventive treatment of episodic migraine |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.94% (rank 956) |
| Evidence Level | L1 (based on the broader migraine indication; no subtype-specific RCTs — see rationale below) |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Structured mechanism-of-action data is currently a data gap in this record. Based on published literature, rimegepant is a small-molecule, highly selective CGRP receptor antagonist, marketed internationally as Nurtec® ODT (USA) and Vydura® (EU), approved for acute treatment of migraine with or without aura and for prevention of episodic migraine in adults.
Migraine with brainstem aura (formerly “basilar-type migraine”) is a clinically recognized subtype within the broader migraine spectrum, not a distinct disease with a separate pathophysiology. Since CGRP-mediated neurovascular signaling is considered central to migraine pathophysiology in general — independent of aura subtype — the mechanism plausibly extends to this subtype. However, none of the identified literature (including the pivotal Phase 3 trials referenced in the review by Blair et al., PMID 36739335) report subtype-stratified outcomes for brainstem aura specifically; existing RCTs enrolled general migraine populations. This means the evidence supports the mechanism-level rationale strongly, but subtype-specific clinical confirmation is currently absent.
One additional consideration: a longitudinal MRA study (PMID 41574090) investigated rimegepant’s effects on cerebral and extracerebral arteries during migraine attacks, which is directly relevant to aura-related cerebrovascular hemodynamics and may eventually help substantiate (or refute) applicability to the brainstem aura subtype.
Clinical Trial Evidence
Currently no related clinical trials registered specifically for migraine with brainstem aura.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41066271 | 2025 | Phase 3 Open-label Long-term Safety | Cephalalgia | Long-term safety/effectiveness of rimegepant 75mg ODT for acute migraine treatment in Chinese adults (single-arm) |
| 35790906 | 2022 | Network Meta-analysis | J Headache Pain | Compares onset of efficacy of rimegepant vs. ubrogepant and lasmiditan for acute migraine treatment |
| 32270407 | 2020 | Regulatory/Drug Profile | Drugs | First approval summary of rimegepant ODT as acute migraine treatment; notes ongoing investigation for prevention and trigeminal neuralgia |
| 36739335 | 2023 | Review | CNS Drugs | Reviews pivotal Phase 3 trial data showing rimegepant superior to placebo for acute and preventive migraine treatment |
| 41366286 | 2025 | Phase 4 Open-label | J Headache Pain | 24-week safety/tolerability of once-daily 75mg rimegepant for episodic migraine prevention |
| 38307667 | 2024 | Review | Handbook Clin Neurol | Overview of CGRP receptor antagonists (gepants), including rimegepant’s approval history and class mechanism |
| 41652664 | 2026 | Retrospective Cohort | Headache | Off-label use of rimegepant for acute migraine treatment in adolescents |
| 33550872 | 2021 | Review | Pain Management | Overview of rimegepant within the new wave of acute migraine treatments (vs. lasmiditan, ubrogepant) |
| 36808268 | 2023 | Phase 1 PK/Safety | Clin Pharmacol Drug Dev | PK and safety of single/multiple-dose rimegepant 75mg ODT in healthy Chinese adults |
| 41133671 | 2026 | Phase 1 PK/Safety | Headache | PK, safety, and tolerability of single-dose rimegepant in children (6–<12 years) with migraine history |
EU Market Information
No marketing authorization records are currently available for this jurisdiction. Rimegepant’s status is recorded as Not marketed (Not Marketed), with 0 licenses on file as of the data cutoff (2026-09-16).
Safety Considerations
Please refer to the SmPC for safety information (key warnings, contraindications, and DDI data are currently data gaps for this record).
- Class-Level Safety Signal (not indication-specific): A pharmacovigilance disproportionality analysis of FAERS data (PMID 41706150) identified a potential signal between CGRP antagonists and cardiac adverse event reporting. Because CGRP is an endogenous vasodilator, theoretical concern exists that CGRP receptor blockade could aggravate coronary vasospasm — mechanistically opposite to what would be needed to treat Prinzmetal (vasospastic) angina, a separate low-scoring TxGNN prediction for this drug that should be treated as a safety monitoring flag, not a repurposing opportunity. This signal should be tracked as rimegepant’s regulatory/safety dossier develops.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Rimegepant’s mechanism (CGRP receptor antagonism) is well-established for migraine broadly, and the drug is already approved and marketed elsewhere for migraine with/without aura. However, migraine with brainstem aura specifically lacks dedicated subtype-stratified trial data, and the drug currently has no marketing authorization in this jurisdiction — warranting a cautious, guardrailed path rather than a full “Go.”
To proceed, the following is needed:
- Official MOA documentation and approved indication text (currently marked as data gaps, DG002 and missing
original_indications) - TFDA/local SmPC warnings and contraindications (currently a Blocking data gap, DG001) — required before any S1 safety evaluation can proceed
- Subtype-stratified (brainstem aura) analysis from existing Phase 3 migraine trial datasets, or a dedicated prospective study
- Continued monitoring of the CGRP-antagonist cardiac safety signal (FAERS disproportionality analysis) as part of ongoing pharmacovigilance
- Confirmation of local market authorization plans/timeline, given current “Not Marketed” / 0-license status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.